Zhang et al. (2016) developed and validated an APOL1 genotyping assay as a precision medicine genetic test for non-diabetic CKD risk prediction (Zhang et al., 2016). There are still ongoing clinical trials (http://www.clinicaltrials.gov; identifiers NCT02234063, NCT04191824 and NCT04910867), assessing the clinical utility of APOL1 genetic testing. Implementation of an APOL1 genotyping assay in a clinical setting could lead to a cost-effective screening program for African Americans who are at high risk for developing CKD and progressing to ESKD. The gene discussed is APOL1; the disease is chronic kidney disease.